key: cord-1007909-zmz8k480
authors: Rutledge, Stephanie M.; Schiano, Thomas D.; Florman, Sander; Im, Gene Y.
title: COVID‐19 Aftershocks on Alcohol‐associated Liver Disease: An Early Cross‐Sectional Report from the U.S. Epicenter (Manuscript HEP4‐20‐0491)
date: 2021-03-05
journal: Hepatol Commun
DOI: 10.1002/hep4.1706
sha: f42ea549bba0ded11d31bf857764a4488497f57e
doc_id: 1007909
cord_uid: zmz8k480

BACKGROUND & AIMS: Experts have forewarned about the COVID‐19 pandemic environment fomenting the rising incidence of alcohol use disorder (AUD) and alcohol‐associated liver disease (ALD). We performed a cross‐sectional study of ALD at our liver transplantation (LT) center, located in the initial U.S. epicenter, New York City (NYC). RESULTS: Centered around the “stay at home” order date in NY state, 3/22/20, we defined 3 time periods: “pre‐COVID” (1/1/20‐3/21/20); “COVID‐quarantine” (3/22/20‐4/22/20); and “declining‐COVID” (4/23/20‐8/25/20). We found a 62% increase in interhospital patient transfers for ALD from pre‐COVID (20/93, 21%) to the declining‐COVID period (43/127, 34%). Our inpatient liver census with ALD also increased: 38% pre‐COVID, 45% COVID‐quarantine and 49% declining‐COVID. Among 30 severe AH patients not responding to medical therapy since 3/22/20, 9 underwent early LT for AH (16% of the total number of early LT during our 8‐year program). Three of 9 early LT recipients reported specific COVID‐related stressors. All 25 previous LT recipients with established abstinence pre‐COVID maintained abstinence at follow‐up visits during declining‐COVID period. Of 6 recipients with sustained alcohol use within 6 months before 3/22/20, half regained abstinence during the declining‐COVID period. CONCLUSION: Our findings help confirm the predictions of rising AUD and ALD as an immediate consequence of the COVID‐19 pandemic. This aftershock particularly affected ethnically diverse ALD patients with high inpatient mortality, reflecting the disproportionate impact of COVID‐19 on underserved and minority populations. Alcohol relapse did not occur in long‐term early LT for AH recipients during the time of COVID‐19. This lends further support to AH being a viable indication for LT, with recipients able to demonstrate ongoing resilience in the face of this unprecedented universal stressor.

The COVID-19 pandemic has been a uniquely universal stressor with widespread health fears, social isolation and severe economic anxiety. Even during peak periods of lockdown, liquors stores remained open as essential businesses, online sales of alcohol increased 262% from 2019 (1) and there has been a spike in self-reported alcohol use.(2) Medical experts have forewarned about the pandemic environment fomenting the rising incidence of alcohol use disorder (AUD) and alcoholassociated liver disease (ALD). (3, 4) To provide an early account of this anticipated aftershock from COVID-19, we performed a crosssectional study of ALD at our liver transplantation (LT) center, located in the initial U.S. epicenter, New York City (NYC).

Centered around the governor's "stay-at-home" order date in New York State, 3/22/20, we defined 3 time periods: "pre-COVID" (1/1/20-3/21/20); "COVID-quarantine" (3/22/20-4/22/20) ; and "declining-COVID" (4/23/20-8/25/20) . The month period from 3/22 to 4/22 was chosen to allow the COVID-related stressors to accumulate. While imprecise, we surmised that there would be some lag time for patients to adopt unhealthy coping strategies leading to changes in alcohol use pattern.

We performed chart reviews of three separate cohorts of patients: 1) all patients transferred to our institution with a primary diagnosis of ALD at time of transfer (confirmed by chart review) during 2020 both prior to and since the COVID pandemic, 2) all patients who underwent early LT for severe

This article is protected by copyright. All rights reserved alcoholic hepatitis (AH) since the onset of the pandemic, and 3) alcohol use since the pandemic started in prior early LT recipients for AH (a prospectively maintained cohort).

A diagnosis of AH was defined using NIHAA criteria for probable or definite AH,(5) based on chart reviews of clinical notes and biopsies where available. ALD was defined as alcohol-associated cirrhosis or AH, and based on chart review of laboratory results, imaging studies and clinical notes.

Patients were included if the treating team felt that ALD was the most likely diagnosis.

Alcohol use was captured by reviewing all patient visits to any provider, where alcohol use was asked about or where alcohol biomarkers were checked. Sustained alcohol use was defined as alcohol consumption of four or more drinks in a day or at least one drink for 4 or more days in succession after LT. A "slip" was defined as any brief alcohol consumption episode followed by resumed abstinence. (6) We defined abstinence as no alcohol use over the preceding 6 months.

COVID-related stressors were defined as a stressor which could be directly attributed to the pandemic. We captured this retrospectively by reviewing all social worker notes, searching for mention of the pandemic resulting in a change in patient's mental health or stress levels.

During the pandemic, a negative COVID nasopharyngeal swab PCR test was required prior to inpatient transfer, but no other changes to our interhospital transfer practice. During the "COVIDquarantine" period, less urgent transfers were discouraged to our dedicated liver medicine service due to hospital rationing.

There was a 62% increase in interhospital patient transfers for ALD from pre-COVID (20/93, 21%) to the declining-COVID period (43/127, 34%) (Supplementary Figure 1) . Transfers to our center peaked in the period from May 22 to June 22, ~2 months after the stay-at-home order, when 13/28

This article is protected by copyright. All rights reserved transfers (46%) had a primary diagnosis of ALD. Geographically, the majority of ALD transfers were from the NYC metropolitan area: Long Island (33%), followed by Brooklyn (17%), the Bronx (17%) and 10% each from Queens, Manhattan and New Jersey.

While our liver service remained "open," a sharp decline was seen in the median total liver census from 44 inpatients pre-COVID to 9 during COVID-quarantine and rising to 23 in the declining-COVID period. This was likely due to the marked decline of interhospital transfers during COVID-quarantine Nearly all (92%) of the 39 AH patients transferred during the declining-COVID period were new referrals (not previously seen at our center). Patients admitted with AH (49 in total) during this period were more likely to be male (p=<0.001), less likely to be Caucasian (p=0.01) and more likely to be of Hispanic ethnicity (p=0.001) and trended towards being sicker based on discriminant function (DF) (p=0.09) than those in the pre-COVID period ( Table 1 ). The overall inpatient mortality rate for AH patients was 31% (21/67), and similarly high within each of the 3 time periods.

Among 30 severe AH patients not responding to medical therapy evaluated from 3/22/20, (28/30 arrived via interhospital transfer, with 22 from a floor bed and 6 from an ICU). A total of 9 patients underwent early LT (<6 months of abstinence) for AH, as previously described. (6) 

This article is protected by copyright. All rights reserved and life-threatening ALD adhered to evidence-based expert consensus (Supplementary Table 1 ). (7) Three out of the 9 early LT recipients reported specific COVID-related stressors: "colleagues [in funeral home] dying from COVID", "drinking more due to the pandemic" and "stress of job as police officer and frustration with inadequate personal protective equipment".

Alcohol Use in Recipients of Early Liver Transplantation for Alcoholic Hepatitis in the Time of COVID-

To determine the impact of COVID-19 stress on early LT for AH recipients, we examined their followup visits and laboratory data in the declining-COVID period. After excluding deaths and recent LT recipients (<6 months post-LT), 42 early LT for AH recipients were analyzed. Somewhat remarkably, all 25 recipients with established abstinence pre-COVID (median 1034 days post-LT [IQR 485-1670] ) maintained abstinence at a follow-visit during the declining-COVID period based on patient interviews and negative alcohol biomarkers (urine ethyl glucuronide and serum phosphatidylethanol), drawn routinely at each visit. (6) Telehealth was used in 34% of visits, with 46% having corresponding laboratory testing. Of the 6 recipients with sustained alcohol use within 6 months before 3/22/20, half continued to drink, but the other half regained abstinence during the declining-COVID period as confirmed by alcohol biomarkers. Eleven recipients did not have a followup visit during this latter period.

This early cross-sectional report from the initial U.S. epicenter of COVID-19 demonstrates a significant aftershock of ALD that may reverberate throughout the country in different stages based on regional COVID-19 infection rates, access to alcohol and socio-political strategies of containment.

Unlike studies using transplant registries, we were able to evaluate the impact of COVID-19 on high risk ALD patients at several program levels and time periods, including those hospitalized/transferred for ALD, LT candidates and recipients in our program of early LT for AH. (6) 

This article is protected by copyright. All rights reserved

Limitations of the study include its retrospective nature and single-center description with small numbers of patients, but it provides a timely account from the initial U.S. epicenter of the COVID-19 pandemic. While it is possible that increases in hospitalized patients with ALD could be related to self-delayed or geographic shifting of liver care from other centers, nationally-representative surveys have demonstrated poorer mental health, increased stress and increased alcohol use during the COVID-19 pandemic.

(2) Throughout 2020, there were contemporaneous stressors, including the racial injustice movement and presidential election which may have affected patients' drinking patterns and resilience, but we found no supporting evidence for this in the medical record, nor upon review with the social work team.

These preliminary findings support the predictions of rising AUD and ALD as an immediate consequence of the COVID-19 pandemic. These aftershocks at our center particularly affected ethnically diverse ALD patients with high inpatient mortality, reflecting the disproportionate impact of COVID-19 on underserved and minority populations in the US. (8) In response, the hepatology community needs to anticipate and prepare for these continued aftershocks of ALD. Developing streamlined care pathways to addiction services and specialists for recovering ALD patients, increased utilization of telehealth, promotion of psychosocial and pharmacologic therapies for AUD and wider implementation of (or rapid referral to) early LT for AH programs based on evidencebased guidelines will be critical. (7, 9) Alcohol relapse did not occur in long-term early LT for AH recipients during the time of COVID-19.

This lends further support to AH being a viable indication for LT, with recipients able to demonstrate ongoing resilience in the face of this unprecedented universal stressor. Further studies are needed to determine the longer-term aftershocks of COVID-19 on patients with ALD.

Rebalancing the 'COVID-19 Effect' on alcohol sales

Changes in Adult Alcohol Use and Consequences During the COVID-19 Pandemic in the US

New challenges in addiction medicine

infection in patients with alcohol and substance use disorders-the perfect storm

COVID-19 hangover: a rising tide of alcohol use disorder and alcohol-associated liver disease

Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: recommendation from the NIAAA Alcoholic Hepatitis Consortia

Early liver transplantation for severe alcoholic hepatitis in the United States-a single

Meeting report: the Dallas consensus conference on liver transplantation for alcohol associated hepatitis

The disproportionate impact of COVID-19

on racial and ethnic minorities in the United States

Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases

Drinks/day prior to admission, median (IQR)

Discriminant function, median (IQR) 62

MELD-Na on admission, median (IQR)

Creatinine in mg/dL, median (IQR)

Length of stay, median days (IQR)

This article is protected by copyright. All rights reserved